BPC-157 and TB-500, injected together, named after the Marvel character who heals from anything. No trial has ever tested the combination in people. The only human data on the pair comes from four patients in a 2021 case series, reached by telephone and asked whether their knees felt better.1
The two compounds have never been studied together in any controlled setting, in humans or in animals. What exists is animal work on each one separately, mostly in rats, plus a great deal of marketing.
It is also the most widely sold thing in this market. Of the 133 sellers we track, 86 list a BPC-157 and TB-500 blend, and 24 of them use the Wolverine name on the product page.2 It is sold as the Wolverine stack, the Wolverine peptide, a BPC-157 and TB-500 blend, and as the base of the GLOW and KLOW blends. See KLOW vs GLOW for how those extensions differ.
The stack in numbers, from our 23 September 2026 capture:
- 86 of 133 tracked sellers list it, 24 under the Wolverine name
- 259 distinct listings, of which 169 do not say how the vial splits between the two compounds
- $68.21 to $195.00 for a 10 mg plus 10 mg vial, median $110
- 1 human study of either compound for injury healing, involving 4 patients on the combination
- 0 trials of the two given together, in people or in animals
Why is it called the Wolverine stack?
Because of the comic book character. It is not a clinical term, not a formulation, and not a product anyone has approved.
The name appeared in forums and spread through social media, and it now drives more search traffic than either compound's actual name. Johns Hopkins described it this month as one of the hottest trends in injectable peptides, in a piece warning about the risks of the grey market it comes from.3 Stanford Medicine ran a similar explainer in August.4
What is in a Wolverine stack?
Usually two compounds, and often you cannot tell how much of each.
Of the 259 distinct blend listings in our September capture, only 90 state how many milligrams of each compound are in the vial.2 The rest say BPC-157 and TB-500 and leave it there. A 20 mg vial could be 10 and 10, or 15 and 5, and the buyer has no way to know.
Two extensions of the same idea are nearly as common. GLOW adds GHK-Cu, at 121 listings across 66 sellers. KLOW adds KPV as well, at 112 listings across 65 sellers.2
Is TB-500 the same as thymosin beta-4?
No, and this distinction matters more than anything else on the page.
The published research is on thymosin beta-4, a 43 amino acid protein that occurs naturally in the body. TB-500 is a 7 amino acid fragment of it. They are not the same molecule, and a review published in The American Journal of Sports Medicine in August notes that the peer-reviewed literature mostly uses pharmaceutical-grade thymosin beta-4, not the TB-500 sold online.5
So when a product page cites thymosin beta-4 research, it is citing studies of something else.
What does the evidence actually show?
One small uncontrolled study for BPC-157, nothing in humans for TB-500, and nothing at all for the two together.
| Human evidence for injury healing | What exists instead | |
|---|---|---|
| BPC-157 | One retrospective case series of 17 knee patients, no control group, outcomes collected by telephone. Graded level 4 | Rat studies showing tendon, muscle and bone benefit, most from the group that discovered the compound |
| TB-500 | None | Animal work, mostly on thymosin beta-4 instead of TB-500 |
| The two combined | Four patients, inside that same case series | Nothing |
The UCLA team behind the August review searched PubMed for both compounds against every musculoskeletal tissue term and found that 67% of the literature is animal work. Their conclusion was that these compounds cannot currently be recommended as a replacement for or an adjunct to standard care.5
Those four combination patients are the entire human record for the stack, so here they are in full. In the 2021 case series, 12 of the 17 patients received BPC-157 alone and 4 received BPC-157 with thymosin beta-4. Three of those four reported improvement. There was no control group, and the authors state that no specific tools were used to measure improvement.1
Why are these two put together?
The claim is that they work on different parts of the same problem, and it is a reasonable-sounding claim that nobody has tested.
BPC-157 is said to act locally: promoting new blood vessel growth at an injury site, through pathways involving VEGF receptor signalling. Thymosin beta-4 acts on actin, the protein cells use to move. That gets framed as the systemic half, helping cells migrate to where they are needed.5
Local repair plus cell delivery. The pairing makes sense on paper, and that is why it spread.
What is missing is any study of the two given together. No animal model, no human trial, no interaction work at all. Two plausible mechanisms do not add up to a tested combination, and they could as easily interfere as complement.
What do the animal studies show?
Quite a lot for one compound, less for the other, nothing on the two together.
For BPC-157: rat Achilles tendon studies using 10 micrograms per kilogram daily improved load to failure and stiffness, with organised collagen where controls had scar. A rabbit study with a 0.8 cm gap cut out of the radius produced roughly twice the callus and a higher union rate than saline, performing about as well as an autologous bone graft.5
Two caveats the review raises about that body of work. Most of it comes from the group that discovered the compound, and none of the studies reported blinding, with groups typically of 4 to 10 animals.5
For TB-500, the animal work is mostly on thymosin beta-4: bone healing in mice, ligament healing in rats. Less of it, and again on the longer molecule, not the fragment being sold.
Is the Wolverine stack FDA approved?
No, and the regulatory position moved twice this year while most pages kept describing the 2023 version of it.
In September 2023 the FDA moved around 17 peptides, including BPC-157 and thymosin beta-4, into Category 2 of its 503A interim list, the tier for substances raising significant safety risks. That effectively ended US compounding of them.
In April 2026 both came out of Category 2, because the people who had nominated them withdrew the nominations. Removal was not a safety verdict and did not make either one compoundable.
Then on 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for inclusion on the 503A Bulks List, BPC-157 and TB-500 among them.6 The agency's own career staff had concluded that none of the seven met its evidentiary standard. The committee voted the other way on six of them, recommending BPC-157 by 8 to 6 with one abstention and TB-500 by the same margin, and rejecting only emideltide.7
FDA staff also told the committee they had encountered many different substances all being sold as BPC-157, with different active molecules in them.7 The regulator and the buyer are running into the same problem from opposite ends.
What it means today: the recommendation is advisory, the FDA has not acted on it as of late September, and neither compound is on the 503A Bulks List. A pharmacy still cannot lawfully compound either one, and nothing about what is sold online has changed.
What it means next: if the FDA follows its committee, BPC-157 and TB-500 would become available through licensed pharmacies with a prescription, the first legitimate supply route either has had. That runs through notice-and-comment rulemaking, which analysts expect to take months rather than weeks, and the Health Secretary has to sign off. A second committee meeting on five more peptides is expected in February 2027.
The Wolverine stack vs BPC-157 alone
The comparison most people actually face, since almost nobody starts with TB-500 by itself.
| BPC-157 alone | The Wolverine stack | |
|---|---|---|
| Typical price | $56.50 for a 10 mg vial, median across 68 sellers | $110 for a 10 mg plus 10 mg blend, median across 15 sellers |
| Human evidence for healing | One case series, 12 patients on BPC-157 alone, 11 reporting improvement, no control group | Four patients inside that same series, three reporting improvement |
| Animal evidence | Tendon, muscle, ligament and bone studies in rats, plus the rabbit bone graft comparison | None of the combination. Each compound separately, and TB-500's is mostly on thymosin beta-4 |
| Trials under way | Two registered in 2026: hamstring strain and rotator cuff repair | None |
| If something goes wrong | You know which compound to stop | You do not |
What changes when you add TB-500. About $54 per cycle at those medians, a second compound with less animal evidence behind it and none in humans for injury, and the loss of any ability to attribute either an effect or a side effect.
What does not change. Neither approach has a controlled human trial behind it. Both are banned in sport. Both are sold with no regulator checking the contents. Adding a second unapproved compound to an unapproved compound does not produce a more established treatment; it produces a less interpretable experiment.
The one argument for the stack is the mechanistic one: local repair and cell migration are different jobs. It is reasonable, it is untested, and it is the same argument a seller makes.
The one argument for BPC-157 alone is that it is the only half of the pair with human data of any kind, however weak, and the only half with trials running. If those trials report something useful in 2027, they will tell you about BPC-157, not about the stack.
Does the price vary much?
More than most people expect for the same two compounds at the same amounts.
Across the sellers listing a 10 mg plus 10 mg blend, prices run from $68.21 to $195.00, with a median of $110.2 Almost three times, for a vial described identically.
Nothing in the data explains the spread. It does not track testing, vial size or anything else we record.
Does the blend save money?
Sometimes, and the small one usually costs more.
At the two most common configurations in our price data, a 5 mg plus 5 mg blend runs a median of $89.50, against about $71.50 for the same milligrams bought as separate vials. That is 25% more for the convenience. A 10 mg plus 10 mg blend runs $110 against about $143 separately, so 23% less.2
The four-compound KLOW blend is where the discount is real: a median of $144.50 against about $239 for the components.
| Blend | Median price | Same amounts bought separately |
|---|---|---|
| BPC-157 5 mg + TB-500 5 mg | $89.50 | about $71.50 |
| BPC-157 10 mg + TB-500 10 mg | $110.00 | about $143.00 |
| KLOW, four compounds | $144.50 | about $239.00 |
One thing a blend costs you regardless: you cannot change the ratio, and if you react badly to it you cannot tell which compound did it.
Is there an established dose?
No. That is the real answer to the most searched question about this stack, and it is why the pages that give you a number are making it up.
Neither compound has a dose established in a human trial, because neither has completed one. The protocols circulating in forums and on seller pages are extrapolated from animal studies, where doses are given per kilogram of a rat.5 Paul Knoepfler, a cell biologist at UC Davis, told reporters there is often no apparent rhyme or reason to the doses people take.8
We do not publish protocols for compounds in this position. The pages that do are not working from anything you could check.
The only number you can check is the one on the vial, and in 169 of the 259 blend listings we track, even that is incomplete, because the seller does not say how the total splits between the two compounds.2
What are the risks?
Three, and the first has nothing to do with either molecule.
You do not know what is in the vial. These are sold as research chemicals, with no regulator checking the contents. See how to read a peptide COA for what a test report can and cannot establish. When 44 products sold online as SARMs were analysed in a comparable market, only 41% matched the amount stated on the label and 39% contained a different unapproved drug.9
BPC-157's healing mechanism is also a cancer pathway question. It promotes new blood vessel growth, which is how it appears to help tissue heal. That same mechanism could in theory accelerate the growth of precancerous cells, a point Knoepfler has made repeatedly, and nobody has tested whether it does.8 The UCLA review lists the concern as theoretical and unstudied.5
Both are banned in sport. BPC-157 falls under WADA's S0 category for non-approved substances, and thymosin beta-4 and its derivatives, including TB-500, are prohibited. Anti-doping laboratories have published detection methods for both.
Three things other pages get wrong
The same three errors repeat across most of the coverage.
"TB-500 is thymosin beta-4." It is not. Thymosin beta-4 is a 43 amino acid protein and TB-500 is a 7 amino acid fragment sold online. Research citing the former is not evidence for the latter.5
"BPC-157 is in FDA Category 2." It left Category 2 in April 2026, and in July an FDA advisory committee recommended adding it to the 503A Bulks List instead.67 Pages published this year still describe the 2023 position.
"The stack has human evidence." The combination has been given to four people in a published study, inside an uncontrolled case series with no measurement tools.1 Pages citing "human studies" for the stack are citing studies of BPC-157 alone, or of thymosin beta-4, or of neither.
So does the Wolverine stack work?
Nobody knows. Anyone who tells you otherwise is selling something, or repeating someone who is.
The rat evidence for BPC-157 is real and fairly consistent. The human evidence for the combination is four people who were phoned up and asked how they felt. Between those two facts is a gap that only a trial can close, and the first trials that could are recruiting now: one for hamstring strain, one after rotator cuff repair.
Until then, what is happening is an experiment that a lot of people are running on themselves, at $90 to $145 a vial, without a control group.
Common questions
What is the Wolverine stack?
BPC-157 and TB-500 injected together, named after the Marvel character. The term comes from forums, not medicine, and no approved product exists under that name or any other for either compound.
Has the Wolverine stack been studied in humans?
Not as a combination. The only human data is four patients inside a 2021 retrospective case series who received BPC-157 with thymosin beta-4, three of whom reported improvement, with no control group and no formal measurement.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43 amino acid protein, and TB-500 is a 7 amino acid fragment sold online. The published research is mostly on the former, so a product page citing thymosin beta-4 studies is citing research on a different molecule.
What is the correct Wolverine stack dosage?
There is not one. Neither compound has a dose established in a human trial, and the protocols circulating online are extrapolated from animal studies dosed per kilogram of a rat. Any page quoting a specific milligram figure for this stack is passing on a convention, not a finding.
Is the Wolverine stack safe?
Unknown, which is not the same as safe. No human safety data exists for the combination at all. The documented concerns are the contents of unregulated vials, a theoretical cancer pathway question for BPC-157, and the absence of any long-term human data for either compound.
Is the Wolverine stack legal?
Neither compound is approved for human use anywhere. They are sold as research chemicals, which is a labelling position and not a permission, and both are banned in competitive sport.
Is a blend cheaper than buying the peptides separately?
It depends on the size. A 5 mg plus 5 mg blend costs about 25% more than the same amounts bought as separate vials, while a 10 mg plus 10 mg blend costs about 23% less, and the four-compound KLOW blend about 40% less.
Is the Wolverine stack better than BPC-157 alone?
Nothing shows that it is. BPC-157 alone has 12 patients of human data and two trials now recruiting; the combination has four patients and none. Adding TB-500 costs about $54 more per 10 mg vial at median prices, and it means that if something helps or something goes wrong, you cannot tell which compound did it.
What is the difference between Wolverine, GLOW and KLOW?
Wolverine is BPC-157 with TB-500. GLOW adds GHK-Cu. KLOW adds KPV on top of that. All three are seller conventions, not formulations anyone has tested.
Is BPC-157 still in the FDA's Category 2?
No. Both BPC-157 and TB-500 left Category 2 in April 2026, after the nominators withdrew their nominations. In July 2026 an FDA advisory committee then voted to recommend adding both to the 503A Bulks List, against the agency's own reviewers. The FDA has not acted on that recommendation, so neither can be lawfully compounded today.
Could BPC-157 become legally available?
Possibly. An FDA advisory committee recommended in July 2026 that BPC-157 and TB-500 be added to the list of substances compounding pharmacies may use. If the FDA follows that recommendation through rulemaking, both would become available with a prescription from a licensed pharmacy. There is no timetable, and the agency is not obliged to follow its committee.
Has anyone studied the two peptides together?
No. There is no animal study and no human trial of the combination. The pairing rests on the idea that one acts locally and the other systemically, which nobody has tested.
Are there side effects?
No human safety data exists for the combination, so there is no side effect profile to quote. The documented concerns are about product contents, the theoretical cancer pathway question for BPC-157, and the absence of any long-term data in people.
Why do so many sellers offer it as one vial?
It is convenient and it sells. The trade-off is that you cannot adjust the ratio, and 169 of the 259 blend listings we track do not tell you what the ratio is.
Citing this page. Peptide Decoding. What Is the Wolverine Stack, and Does It Work? Vendor listing and price figures from the 23 September 2026 capture of 133 sellers. https://peptidedecoding.com/guides/wolverine-stack
Sources
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine 2021;27(4):8-13. The only human study of BPC-157 for joint or tendon problems, read at abstract level. 17 patients injected, 16 reached by telephone six months to a year later, 12 given BPC-157 alone and 4 given BPC-157 with thymosin beta-4. Eleven of the twelve and three of the four reported significant improvement. The authors state that no specific tools were used to measure improvement.
- Peptide Decoding vendor price capture, 23 September 2026. peptidedecoding.com/prices. Our own data: 259 distinct BPC-157 and TB-500 blend listings across 86 of 133 tracked sellers, 24 of which use the Wolverine name; 90 listings state both component amounts. Blend prices are medians of listings stating both sizes; component comparisons use the median price per mg for each compound sold as a single vial in stock.
- Johns Hopkins University. The compounding problem of peptides, 16 September 2026. hub.jhu.edu. University news feature, read via search results because the site blocks automated access. Describes the Wolverine stack as one of the hottest trends in injectable peptides and reports Johns Hopkins scientists' warnings about the unregulated market supplying it.
- Stanford Medicine. Peptides are buzzing: but what does the science say?, 10 August 2026. med.stanford.edu. University explainer covering stacking, research-grade labelling and the Wolverine stack, including a researcher finding molecules she discovered in mice being sold for self-injection.
- Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American Journal of Sports Medicine, published online 11 August 2026. doi:10.1177/03635465261464420. Open access scoping review, read in full. Source for the evidence grading of each compound, the TB-500 versus thymosin beta-4 distinction, the 67% preclinical figure and the review's conclusion.
- US Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov. The agency's own meeting page, listing the seven bulk drug substances considered for the 503A Bulks List and the uses reviewed for each: BPC-157 for ulcerative colitis, TB-500 for wound healing, alongside KPV, MOTS-c, Emideltide, Semax and Epitalon.
- News coverage of the 23 July 2026 committee votes, including ABC News and The Hill, plus the National Community Pharmacists Association summary of 31 July 2026. National reporting from the meeting, read via search results and consistent across outlets: BPC-157 recommended 8 to 6 with one abstention and TB-500 by the same margin, against the written recommendation of FDA career staff. The Hill is the source for FDA staff telling the committee they had found many substances sold as BPC-157 containing different active molecules. NCPA reported that six of the seven peptides were recommended, that emideltide was rejected, and that the Health Secretary must approve any addition. FDA summary minutes were not posted at the time of writing; substitute them when they appear.
- Press reporting quoting Paul Knoepfler, cell and molecular biologist at the University of California, Davis. Press interview, read via search results. Makes the point that the angiogenic mechanism proposed for tissue healing could in theory accelerate precancerous cell growth, and that clinical trials are the only way to know.
- Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 2017;318(20):2004-2010. doi:10.1001/jama.2017.17069. Primary analysis of 44 products bought online. Concerns SARMs rather than peptides, cited because the sales channel is the same.